Brainstorm Cell Therapeutics Inc. received a notice from Nasdaq that its common stock would be delisted due to non-compliance with the minimum bid price requirement, but the company has requested a hearing to appeal the delisting determination and has been granted a temporary exception until October 21, 2024 to regain compliance.